[DOI] [PubMed] [Google Scholar] 94.Nahra R, Wang T, Gadde KM, Oscarsson J, Stumvoll M, Jermutus L, Hirshberg B, Ambery P
As a GLP-1 (glucagon-like peptide-1) receptor agonist, Ozempic stands out from other medications in its class due to several unique characteristics that directly benefit our patients
Appetite drops
Patients should be counseled that evidence for low-dose regimens specifically for inflammation is limited, and alternative evidence-based anti-inflammatory strategies (lifestyle modification, statins, specific anti-inflammatory medications for diagnosed conditions) should be prioritized
These challenges were ultimately overcome through molecular modification, long-acting formulations, and a more sophisticated understanding of receptor pharmacology, including biased agonism and doseexposure relationships (Mller et al., 2019)
Juries respond to visible effort and medical accountability, says Rothbaum